Impact of adding semaglutide in a person with type 1 diabetes: A case report

Overweight woman with type 1 diabetes (T1D) treated with insulin pump and what else?Our understanding of type 1 diabetes and our capacity to standardize care as well as reduce the burden connected to the daily fluctuations of blood sugar remain largely unsatisfactory.The daily life of a person with T1D shows that insulin therapy alone does not suffice to get the targeted glucose control in a majority of patients.In the literature, data on the use of agonists of the receptor of Glucagon-like peptide-1 (AR GLP-1) in the patient with T1D are very few, but let us imagine that a positive impact can be expected.In particular, semaglutide has been studied a lot in the reduction of cardiovascular risk in persons with type 2 diabetes (T2D), but there is no data to date in the patient with T1D, neither on glycemic control, nor, or even less, on secondary complications.This article exposes the clinical case of a woman with T1D, treated by insulin pump with then the addition of semaglutide.Using a flash type continuous glucose monitoring system, the monitoring parameters will be illustrated.The addition of semaglutide seems to have the ability to reduce the glucose variability, improve the glucose control and reduce weight in a patient with long time evolving T1D.